Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status-Reference-Cited by-同舟云学术

Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status

Published:2010-05 Issue:5 Volume:5 Page:591-596
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Onitsuka Takamitsu,Uramoto Hidetaka,Ono Kenji,Takenoyama Mitsuhiro,Hanagiri Takeshi,Oyama Tsunehiro,Izumi Hiroto,Kohno Kimitoshi,Yasumoto Kosei

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Vital Statistics;Statistics and Information Department,2001

2. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe;Janssen-Heijnen;Lung Cancer,2001

3. The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study;Goya;Lung Cancer,2005

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering c-Met-CAR NK-92 cells as a promising therapeutic candidate for lung adenocarcinoma;Pharmacological Research;2023-02

2. Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET;Cancer Research;2022-04-11

3. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer;Biochemical Pharmacology;2021-07

4. MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study;Translational Oncology;2020-12

5. MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?;Annals of Translational Medicine;2020-11